Hot Features
SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer’s disease and agitation; SCI-210 for the treatment of autism spectrum disorder and status epilepti... SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer’s disease and agitation; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company sells hemp seed oil-based products and others. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and palmitoylethanolamide oral tablets CannAmide in softgel capsule form. It also has an agreement with The Israeli Medical Center for Alzheimer’s to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer’s disease and agitation; and a collaboration with Clearmind Medicine Inc. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -1.2 | -14.1176470588 | 8.5 | 9.37 | 7.3 | 28708 | 8.52307124 | CS |
| 4 | 3.08 | 72.9857819905 | 4.22 | 15.79 | 4.0951 | 2444980 | 10.70566813 | CS |
| 12 | 3.01 | 70.1631701632 | 4.29 | 15.79 | 2.98 | 1152465 | 9.18944729 | CS |
| 26 | 5.71 | 359.119496855 | 1.59 | 15.79 | 0.4704 | 1053177 | 5.41807002 | CS |
| 52 | 7.008 | 2400 | 0.292 | 15.79 | 0.29 | 1992242 | 4.64468447 | CS |
| 156 | 6.77 | 1277.35849057 | 0.53 | 15.79 | 0.1407 | 2658762 | 2.09434974 | CS |
| 260 | 0.3 | 4.28571428571 | 7 | 15.79 | 0.1407 | 2149269 | 1.96009266 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.